Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Share-based Compensation (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Share-based Compensation data on record, last reported at $8.9 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 8.91% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $36.2 million, up 5.77%, while the annual FY2025 figure was $36.2 million, 5.77% up from the prior year.
  • Share-based Compensation reached $8.9 million in Q4 2025 per CLDX's latest filing, up from $8.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.8 million in Q4 2024 and bottomed at $1.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $5.9 million, with a median of $6.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 149.8% in 2021, then dropped 8.91% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2021, then surged by 43.57% to $4.5 million in 2022, then soared by 59.98% to $7.2 million in 2023, then soared by 35.61% to $9.8 million in 2024, then decreased by 8.91% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $8.9 million in Q4 2025, $8.8 million in Q3 2025, and $9.2 million in Q2 2025.